Jana Care, a cutting-edge home blood testing service, provides a comprehensive one-stop solution from diagnostic testing to resolution
Published Mar. 02, 2024
By Hopkins Medtech
On November 8th, Jana Care announced the completion of a $6 million Series B financing round to facilitate the commercialization of self-monitoring blood tests for kidney and heart diseases.
Established in 2011 and headquartered in Watertown, USA, Jana Care is a home in vitro diagnostics (IVD) company. It specializes in developing real-time diagnostic te kidney disease, and diabetes for screening and management. Through its proprietary digital connectivity platform, individuals can perform real-time tests at home using fingertip blood samples. Additionally, Jana Care is actively developing new testing projects, including detection for NT-proBNP, potassium, and serum creatinine. The company is committed to providing convenient and efficient diagnostic solutions to improve patient quality of life and promote health management. chnology targeting chronic diseases such as heart failure, chronic
Jana Care has developed a paper-based biomarker test strip, transforming the testing environment from wet chemistry laboratories to dry chemical test strips. The strip utilizes a multi-layered, porous material design with layers containing applied dry chemical substances. When blood comes into contact with this design, propelled by capillary action, it flows through the paper strip and activates the applied dry chemicals. During this process, the dry chemicals generate specific signals that the Aina system can read and interpret. This innovative technology makes biomarker detection more efficient and convenient, providing a reliable tool for screening and managing chronic diseases.
Aina is an optical reader capable of reading signals on the test strip, including colorimetry and fluorescence. Jana Care’s unique optical design makes the reader compact, and affordable and supports the analysis of multiple determinations on the same device. This outstanding flexibility gives Aina a wide range of applications, making it a versatile and efficient tool, and offering users a reliable and convenient optical interpretation solution.
Ultimately, Aina transmits the test results to doctors, enabling remote medical consultations, including diagnostic tests. Using the phone as an interconnected platform has significant advantages: if Jana Care subsequently launches test strips with additional testing services, new tests can be programmed on the Aina device. It can also remotely identify devices that need maintenance and troubleshoot them to ensure quality and reliability in large-scale use. This highly intelligent and remote management approach provides a more convenient and efficient solution for medical services, allowing patients and doctors greater flexibility in remote monitoring and diagnosis.
Of course, the beautiful vision of a platform is not only achieved through description but also requires market recognition. Currently, Jana Care focuses on the areas of congestive heart failure and chronic kidney disease, determining patients who need clinical follow-up through at-home testing.
According to survey data from Grand View Research, in the point-of-care testing (POCT) sub-segment, the home end-use sub-market is expected to grow at the fastest rate of 7.2% from 2023 to 2030. Compared to other testing solutions, Jana Care can not only provide services at a lower cost but can also cover a broader range of areas in a more straightforward manner. This reflects the growing market demand for convenient and cost-effective home health management tools, highlighting Jana Care’s competitive advantage in meeting this demand. These market trends suggest that Jana Care’s platform is poised for robust development in the future, providing more advanced and convenient health management solutions for patients and healthcare professionals.
However, currently, it is regrettable that Jana Care’s at-home self-check platform has not yet received approval from the U.S. Food and Drug Administration (FDA). In a market with numerous at-home blood self-test products, how to stand out in the competition becomes a consideration.
Despite facing challenges, as mentioned earlier, Jana Care is expected to find a breakthrough in this fiercely competitive market. North America, being a major market in the POCT field, provides ample room for growth for such emerging companies. We will continue to monitor Jana Care’s future development to see if it can distinguish itself.
